连接式智能笔帽对1型糖尿病成人血糖控制与治疗满意度的随机试验
本研究为研究者发起的随机、开放标签、平行组试验,在1型糖尿病多针注射且血糖管理欠佳的成人中比较连接式胰岛素笔帽与蓝牙禁用的相同笔帽。结果显示连接组血糖高于13.9 mmol/L的时间比例和血糖标准差降低,治疗满意度无组间差异,低血糖回避行为减少。
要点
- 连接式笔帽降低血糖高于13.9 mmol/L的时间比例和血糖标准差。
- 治疗满意度评分无组间差异,低血糖回避行为显著减少。
- 无不良事件或器械相关严重不良事件。
核心结论
- 在常规临床中,连接式笔帽降低1型糖尿病管理欠佳成人的严重高血糖、血糖变异性和低血糖回避行为,不影响治疗满意度。
研究设计与样本
- 研究者发起的随机、开放标签、平行组试验,在欧洲公立医院进行8周。
主要发现
- 连接组血糖高于13.9 mmol/L时间比例平均差为-4.8个百分点(95%CI -9.5至-0.1;p=0.045)。
- 连接组血糖标准差平均差为-0.35 mmol/L(95%CI -0.64至-0.06;p=0.018)。
- HbA1c呈边缘性降低-3.5 mmol/mol(-0.32%)(95%CI -7.1至0.0 mmol/mol;-0.65至0.00%;p=0.050)。
- 符合方案分析提示依从使用者目标范围内时间绝对增加8%。
- 治疗满意度评分无组间差异,低血糖恐惧调查回避行为在治疗组显著减少(β=-2.44;95%CI -4.45至-0.43;p=0.019)。
临床怎么用
- 可考虑将低负担、数据驱动的连接式笔帽整合入公立糖尿病照护,以改善严重高血糖和血糖变异性。
- 需更大规模、更长疗程试验评估该干预的持久性和成本效益。
局限性
- 开放标签设计,未设盲。
- 为单中心研究,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Connected insulin pens and smart caps automatically capture dosing data and can prompt patients about missed prandial boluses, but independent randomised evidence in type 1 diabetes is scarce. We aimed to assess whether a connected insulin pen cap improves glycaemic management and treatment satisfaction compared with an otherwise identical non-connected cap. METHODS: We conducted an investigator-initiated, randomised, open-label, parallel-group trial in a European public hospital over 8 weeks. Adults with type 1 diabetes treated with multiple daily injections and who had suboptimal glycaemic management (baseline time above range [>10.0 mmol/l, >180 mg/dl] >25%) were randomly assigned (1:1) to a connected pen cap (Insulclock 2.0; Insulcloud, Madrid, Spain) or an identical cap for which the Bluetooth connectivity had been disabled (disconnected). Allocation was performed using opaque sealed envelopes, and no masking was applied. The primary outcome was time above range, with two thresholds (>10.0 mmol/l, >180 mg/dl and >13.9 mmol/l, >250 mg/dl) based on intermittently scanned CGM downloads. Analyses followed the intention-to-treat principle, using longitudinal mixed models and multiple imputation. Secondary outcomes included time in range, glycaemic variability (standard deviation and coefficient of variation), HbA1c and patient-reported outcomes (treatment satisfaction and fear of hypoglycaemia). RESULTS: Forty-two participants were randomised for inclusion in the study (21 per group: 25 women, 17 men). One withdrew before baseline, leaving 41 in the intention-to-treat analysis. Compared with the control group, the connected-cap group had lower time above range >13.9 mmol/l (mean difference -4.8 percentage points; 95% CI -9.5, -0.1; p=0.045) and reduced glucose standard deviation (-0.35 mmol/l; 95% CI -0.64, -0.06; p=0.018). HbA1c showed a borderline reduction of -3.5 mmol/mol (-0.32%) (95% CI -7.1, 0.0 mmol/mol; -0.65, 0.00%; p=0.050). Per-protocol analyses suggested an 8% absolute increase in time in range among adherent users. No adverse events or device-related serious adverse events occurred. No between-group differences were observed in treatment satisfaction scores, and avoidance behaviours based on the hypoglycaemia fear survey significantly decreased in the treatment group (β=-2.44; 95% CI -4.45, -0.43; p=0.019). CONCLUSIONS/INTERPRETATION: In routine clinical care, use of a connected pen cap reduced severe hyperglycaemia, glycaemic variability and hypoglycaemia avoidance behaviours in adults with type 1 diabetes and suboptimal glycaemic management, without affecting treatment satisfaction. These findings support the integration of low-burden, data-driven tools into public diabetes care. Larger and longer trials should evaluate the durability and cost-effectiveness of these interventions. TRIAL REGISTRATION: ClinicalTrials.gov NCT06845891 FUNDING: Investigator-initiated study without industry funding; devices were procured by the hospital. Funders had no role in study design, conduct, analysis or reporting.
引用
- Sebastian-Valles F, Sager-La Ganga C, Justel Enriquez A, et al. Analysis of glycaemic control and treatment satisfaction with a connected smart pen cap in adults with type 1 diabetes: a randomised, open-label, parallel-group trial. Diabetologia. 2026. PMID: 41634174. doi:10.1007/s00125-026-06674-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。